Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis
Rheumatoid arthritis and juvenile arthritis represent the commonest diseases complicated by AA amyloidosis in developed countries. Up to 5% of patients with rheumatoid arthritis will develop AA amyloidosis, with renal failure being the commonest cause of mortality. To date, treatment of this conditi...
Gespeichert in:
| Veröffentlicht in: | Internal medicine journal 2004-09, Vol.34 (9-10), p.570-572 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 572 |
|---|---|
| container_issue | 9-10 |
| container_start_page | 570 |
| container_title | Internal medicine journal |
| container_volume | 34 |
| creator | Smith, G. R. Tymms, K. E. Falk, M. |
| description | Rheumatoid arthritis and juvenile arthritis represent the commonest diseases complicated by AA amyloidosis in developed countries. Up to 5% of patients with rheumatoid arthritis will develop AA amyloidosis, with renal failure being the commonest cause of mortality. To date, treatment of this condition has focused on suppressing the underlying inflammatory condition with drugs such as cyclophosphamide and chlorambucil, but both these drugs are associated with myelotoxicity, leukaemia and sterility. Tumour necrosis factor‐α (TNF‐α) is thought to be involved in amyloid deposition. The efficacy of anti‐TNF‐α therapy (etanercept) in the treatment of renal amyloidosis complicating rheumatoid arthritis is demonstrated here and the current scientific data on this subject are presented. (Intern Med J 2004; 34: 570−572) |
| doi_str_mv | 10.1111/j.1445-5994.2004.00605.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66971472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66971472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4325-a4260359c4110ae926e7f6fb1d4a64009e41c030e4eea8bf5aaee916c28ea8413</originalsourceid><addsrcrecordid>eNqNkMtvEzEQhy1ERR_wL6C9wG2X8WO9scQFRW3akoKQeBytiTNLHfYRbEck_32dJmqvzMVjzffz42Os4FDxXB9WFVeqLmtjVCUAVAWgoa62L9jZ0-DlY69KMCBP2XmMKwDeSKNesVNeq4kQDT9jny8TDhQcrVORAmHqaUjF2BaBBuwK7Hfd6Jdj9LFwY7_uvMPkh99FuKdNjynPCgzpPvjk42t20mIX6c1xvWA_ri6_T6_L-dfZzfTTvHRKirpEJTTI2jjFOSAZoalpdbvgS4VaARhS3IEEUkQ4WbQ1IpHh2olJ3isuL9j7w7nrMP7dUEy299FR1-WfjJtotTYNV43I4OQAujDGGKi16-B7DDvLwe5F2pXd-7J7X3Yv0j6KtNscfXu8Y7PoafkcPJrLwLsjgNFh1wYcnI_PnBbS5MrcxwP3z3e0--8H2Ju729zkeHmI-5ho-xTH8MfqRja1_fVlZpvp_Oqb-DmzXD4AiF-eRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66971472</pqid></control><display><type>article</type><title>Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Smith, G. R. ; Tymms, K. E. ; Falk, M.</creator><creatorcontrib>Smith, G. R. ; Tymms, K. E. ; Falk, M.</creatorcontrib><description>Rheumatoid arthritis and juvenile arthritis represent the commonest diseases complicated by AA amyloidosis in developed countries. Up to 5% of patients with rheumatoid arthritis will develop AA amyloidosis, with renal failure being the commonest cause of mortality. To date, treatment of this condition has focused on suppressing the underlying inflammatory condition with drugs such as cyclophosphamide and chlorambucil, but both these drugs are associated with myelotoxicity, leukaemia and sterility. Tumour necrosis factor‐α (TNF‐α) is thought to be involved in amyloid deposition. The efficacy of anti‐TNF‐α therapy (etanercept) in the treatment of renal amyloidosis complicating rheumatoid arthritis is demonstrated here and the current scientific data on this subject are presented. (Intern Med J 2004; 34: 570−572)</description><identifier>ISSN: 1444-0903</identifier><identifier>EISSN: 1445-5994</identifier><identifier>DOI: 10.1111/j.1445-5994.2004.00605.x</identifier><identifier>PMID: 15482271</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Pty</publisher><subject>AA amyloidosis ; Amyloidosis ; Amyloidosis - complications ; Amyloidosis - drug therapy ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - complications ; Biological and medical sciences ; Etanercept ; Female ; General aspects ; Humans ; Immunoglobulin G - therapeutic use ; Kidney Diseases - complications ; Kidney Diseases - drug therapy ; Medical sciences ; Metabolic diseases ; Middle Aged ; nephrotic syndrome ; Nephrotic Syndrome - complications ; Nephrotic Syndrome - drug therapy ; Other metabolic disorders ; Receptors, Tumor Necrosis Factor - therapeutic use ; rheumatoid arthritis ; Serum Amyloid A Protein - analysis ; Serum Amyloid A Protein - metabolism ; treatment ; tumour necrosis factor-α</subject><ispartof>Internal medicine journal, 2004-09, Vol.34 (9-10), p.570-572</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4325-a4260359c4110ae926e7f6fb1d4a64009e41c030e4eea8bf5aaee916c28ea8413</citedby><cites>FETCH-LOGICAL-c4325-a4260359c4110ae926e7f6fb1d4a64009e41c030e4eea8bf5aaee916c28ea8413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1445-5994.2004.00605.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1445-5994.2004.00605.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16239999$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15482271$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, G. R.</creatorcontrib><creatorcontrib>Tymms, K. E.</creatorcontrib><creatorcontrib>Falk, M.</creatorcontrib><title>Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis</title><title>Internal medicine journal</title><addtitle>Intern Med J</addtitle><description>Rheumatoid arthritis and juvenile arthritis represent the commonest diseases complicated by AA amyloidosis in developed countries. Up to 5% of patients with rheumatoid arthritis will develop AA amyloidosis, with renal failure being the commonest cause of mortality. To date, treatment of this condition has focused on suppressing the underlying inflammatory condition with drugs such as cyclophosphamide and chlorambucil, but both these drugs are associated with myelotoxicity, leukaemia and sterility. Tumour necrosis factor‐α (TNF‐α) is thought to be involved in amyloid deposition. The efficacy of anti‐TNF‐α therapy (etanercept) in the treatment of renal amyloidosis complicating rheumatoid arthritis is demonstrated here and the current scientific data on this subject are presented. (Intern Med J 2004; 34: 570−572)</description><subject>AA amyloidosis</subject><subject>Amyloidosis</subject><subject>Amyloidosis - complications</subject><subject>Amyloidosis - drug therapy</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Biological and medical sciences</subject><subject>Etanercept</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Kidney Diseases - complications</subject><subject>Kidney Diseases - drug therapy</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>nephrotic syndrome</subject><subject>Nephrotic Syndrome - complications</subject><subject>Nephrotic Syndrome - drug therapy</subject><subject>Other metabolic disorders</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>rheumatoid arthritis</subject><subject>Serum Amyloid A Protein - analysis</subject><subject>Serum Amyloid A Protein - metabolism</subject><subject>treatment</subject><subject>tumour necrosis factor-α</subject><issn>1444-0903</issn><issn>1445-5994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtvEzEQhy1ERR_wL6C9wG2X8WO9scQFRW3akoKQeBytiTNLHfYRbEck_32dJmqvzMVjzffz42Os4FDxXB9WFVeqLmtjVCUAVAWgoa62L9jZ0-DlY69KMCBP2XmMKwDeSKNesVNeq4kQDT9jny8TDhQcrVORAmHqaUjF2BaBBuwK7Hfd6Jdj9LFwY7_uvMPkh99FuKdNjynPCgzpPvjk42t20mIX6c1xvWA_ri6_T6_L-dfZzfTTvHRKirpEJTTI2jjFOSAZoalpdbvgS4VaARhS3IEEUkQ4WbQ1IpHh2olJ3isuL9j7w7nrMP7dUEy299FR1-WfjJtotTYNV43I4OQAujDGGKi16-B7DDvLwe5F2pXd-7J7X3Yv0j6KtNscfXu8Y7PoafkcPJrLwLsjgNFh1wYcnI_PnBbS5MrcxwP3z3e0--8H2Ju729zkeHmI-5ho-xTH8MfqRja1_fVlZpvp_Oqb-DmzXD4AiF-eRg</recordid><startdate>200409</startdate><enddate>200409</enddate><creator>Smith, G. R.</creator><creator>Tymms, K. E.</creator><creator>Falk, M.</creator><general>Blackwell Science Pty</general><general>Blackwell Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200409</creationdate><title>Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis</title><author>Smith, G. R. ; Tymms, K. E. ; Falk, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4325-a4260359c4110ae926e7f6fb1d4a64009e41c030e4eea8bf5aaee916c28ea8413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>AA amyloidosis</topic><topic>Amyloidosis</topic><topic>Amyloidosis - complications</topic><topic>Amyloidosis - drug therapy</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Biological and medical sciences</topic><topic>Etanercept</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Kidney Diseases - complications</topic><topic>Kidney Diseases - drug therapy</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>nephrotic syndrome</topic><topic>Nephrotic Syndrome - complications</topic><topic>Nephrotic Syndrome - drug therapy</topic><topic>Other metabolic disorders</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>rheumatoid arthritis</topic><topic>Serum Amyloid A Protein - analysis</topic><topic>Serum Amyloid A Protein - metabolism</topic><topic>treatment</topic><topic>tumour necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, G. R.</creatorcontrib><creatorcontrib>Tymms, K. E.</creatorcontrib><creatorcontrib>Falk, M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Internal medicine journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, G. R.</au><au>Tymms, K. E.</au><au>Falk, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis</atitle><jtitle>Internal medicine journal</jtitle><addtitle>Intern Med J</addtitle><date>2004-09</date><risdate>2004</risdate><volume>34</volume><issue>9-10</issue><spage>570</spage><epage>572</epage><pages>570-572</pages><issn>1444-0903</issn><eissn>1445-5994</eissn><abstract>Rheumatoid arthritis and juvenile arthritis represent the commonest diseases complicated by AA amyloidosis in developed countries. Up to 5% of patients with rheumatoid arthritis will develop AA amyloidosis, with renal failure being the commonest cause of mortality. To date, treatment of this condition has focused on suppressing the underlying inflammatory condition with drugs such as cyclophosphamide and chlorambucil, but both these drugs are associated with myelotoxicity, leukaemia and sterility. Tumour necrosis factor‐α (TNF‐α) is thought to be involved in amyloid deposition. The efficacy of anti‐TNF‐α therapy (etanercept) in the treatment of renal amyloidosis complicating rheumatoid arthritis is demonstrated here and the current scientific data on this subject are presented. (Intern Med J 2004; 34: 570−572)</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Pty</pub><pmid>15482271</pmid><doi>10.1111/j.1445-5994.2004.00605.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1444-0903 |
| ispartof | Internal medicine journal, 2004-09, Vol.34 (9-10), p.570-572 |
| issn | 1444-0903 1445-5994 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66971472 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | AA amyloidosis Amyloidosis Amyloidosis - complications Amyloidosis - drug therapy Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - complications Biological and medical sciences Etanercept Female General aspects Humans Immunoglobulin G - therapeutic use Kidney Diseases - complications Kidney Diseases - drug therapy Medical sciences Metabolic diseases Middle Aged nephrotic syndrome Nephrotic Syndrome - complications Nephrotic Syndrome - drug therapy Other metabolic disorders Receptors, Tumor Necrosis Factor - therapeutic use rheumatoid arthritis Serum Amyloid A Protein - analysis Serum Amyloid A Protein - metabolism treatment tumour necrosis factor-α |
| title | Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T20%3A39%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etanercept%20treatment%20of%20renal%20amyloidosis%20complicating%20rheumatoid%20arthritis&rft.jtitle=Internal%20medicine%20journal&rft.au=Smith,%20G.%20R.&rft.date=2004-09&rft.volume=34&rft.issue=9-10&rft.spage=570&rft.epage=572&rft.pages=570-572&rft.issn=1444-0903&rft.eissn=1445-5994&rft_id=info:doi/10.1111/j.1445-5994.2004.00605.x&rft_dat=%3Cproquest_cross%3E66971472%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66971472&rft_id=info:pmid/15482271&rfr_iscdi=true |